中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2010年
2期
76-79
,共4页
王丹丹%张华勇%冯学兵%华冰珠%刘布骏%王红%叶圣勤%胡祥%曾小峰%侯亚义%孙凌云
王丹丹%張華勇%馮學兵%華冰珠%劉佈駿%王紅%葉聖勤%鬍祥%曾小峰%侯亞義%孫凌雲
왕단단%장화용%풍학병%화빙주%류포준%왕홍%협골근%호상%증소봉%후아의%손릉운
红斑狼疮,系统性%间质干细胞%脐带%移植
紅斑狼瘡,繫統性%間質榦細胞%臍帶%移植
홍반랑창,계통성%간질간세포%제대%이식
Lupus erythematosus,systemic%Mesenchymal stem cells%Umbilical cord%Transplantation
目的 探讨脐带间充质干细胞(UC-MSCs)移植治疗重症难治性系统性红斑狼疮(SLE)的疗效及安全性.方法 UC-MSCs移植治疗12例SLE患者,评价患者移植前后临床表现和实验室检查指标的变化.结果 UC-MSCs移植后,12例SLE患者随访1～26个月.移植后1个月SLE疾病活动指数(SLEDAI)由(18±4)分降低为(10±4)分(12例,P＜0.01),3个月时持续降为(7±4)分(9例).UC-MSCs移植后1个月尿蛋白定量(24 h)由(3359±1248)mg降低为(2103±749)mg(9例,P＜0.01),移植后3个月[(1427±616)mg与(3342±1333)mg,8例,P＜0.01],2例患者随访至26个月尿蛋白持续下降.5例肾功能不全者血清肌酐由移植前(416±250)μmol/L降至移植后1个月(264±119)μmol/L(P＜0.05);移植后3个月降至(226±103)μmol/L,与移植前比差异有统计学意义(P＜0.05).10例低蛋白血症患者移植后1个月血清白蛋白显著上升[(24±4)g/L与(29±3)g/L,P=0.01],3个月上升至(30±4)g/L.4例患者移植后血小板显著上升,3例患者移植后血清补体C3升高.所有患者均无移植相关并发症.结论 UC-MSCs移植治疗重症SLE安全有效,长期疗效需进一步随访观察.
目的 探討臍帶間充質榦細胞(UC-MSCs)移植治療重癥難治性繫統性紅斑狼瘡(SLE)的療效及安全性.方法 UC-MSCs移植治療12例SLE患者,評價患者移植前後臨床錶現和實驗室檢查指標的變化.結果 UC-MSCs移植後,12例SLE患者隨訪1～26箇月.移植後1箇月SLE疾病活動指數(SLEDAI)由(18±4)分降低為(10±4)分(12例,P＜0.01),3箇月時持續降為(7±4)分(9例).UC-MSCs移植後1箇月尿蛋白定量(24 h)由(3359±1248)mg降低為(2103±749)mg(9例,P＜0.01),移植後3箇月[(1427±616)mg與(3342±1333)mg,8例,P＜0.01],2例患者隨訪至26箇月尿蛋白持續下降.5例腎功能不全者血清肌酐由移植前(416±250)μmol/L降至移植後1箇月(264±119)μmol/L(P＜0.05);移植後3箇月降至(226±103)μmol/L,與移植前比差異有統計學意義(P＜0.05).10例低蛋白血癥患者移植後1箇月血清白蛋白顯著上升[(24±4)g/L與(29±3)g/L,P=0.01],3箇月上升至(30±4)g/L.4例患者移植後血小闆顯著上升,3例患者移植後血清補體C3升高.所有患者均無移植相關併髮癥.結論 UC-MSCs移植治療重癥SLE安全有效,長期療效需進一步隨訪觀察.
목적 탐토제대간충질간세포(UC-MSCs)이식치료중증난치성계통성홍반랑창(SLE)적료효급안전성.방법 UC-MSCs이식치료12례SLE환자,평개환자이식전후림상표현화실험실검사지표적변화.결과 UC-MSCs이식후,12례SLE환자수방1～26개월.이식후1개월SLE질병활동지수(SLEDAI)유(18±4)분강저위(10±4)분(12례,P＜0.01),3개월시지속강위(7±4)분(9례).UC-MSCs이식후1개월뇨단백정량(24 h)유(3359±1248)mg강저위(2103±749)mg(9례,P＜0.01),이식후3개월[(1427±616)mg여(3342±1333)mg,8례,P＜0.01],2례환자수방지26개월뇨단백지속하강.5례신공능불전자혈청기항유이식전(416±250)μmol/L강지이식후1개월(264±119)μmol/L(P＜0.05);이식후3개월강지(226±103)μmol/L,여이식전비차이유통계학의의(P＜0.05).10례저단백혈증환자이식후1개월혈청백단백현저상승[(24±4)g/L여(29±3)g/L,P=0.01],3개월상승지(30±4)g/L.4례환자이식후혈소판현저상승,3례환자이식후혈청보체C3승고.소유환자균무이식상관병발증.결론 UC-MSCs이식치료중증SLE안전유효,장기료효수진일보수방관찰.
Objective To explore the clinical efficacy and safety of umbilical cord derived mesenchymal stem cells transplantation(UC-MSCT)for patients with refractory systemic lupus erythematosus (SLE).Methods Twelve patients with refractory SLE were enrolled in this study.UC-MSCs(≥106/kg cell number)were infused intravenously for each patient. The clinical manifestations and laboratory parameters were compared before and after MSCT. Results The twelve patients were followed up for one to twenty-six months after MSCT.The systemic lupus erythematosus disease activity index(SLEDAI)score decreased from 18±4 to 10±4 one month after MSCT(n=12,P＜0.01)and then decreased to 7±4 at three month follow-up.Nine patients showed improvement of 24 h proteinuria[(2103±749)mg vs(3359±1248)mg,P＜0.01]one month after MSCT.Further improvement of 24 h proteinuria was observed in eight patients[(1427±616)mg vs(3342±1333)mg,P＜0.01]at three months post MSCT.Serum creatinine of five patients decreased significantly and ten patients showed an increase of serum albumin. Serum complement C3 increased in three patients and four patients showed obvious amelioration of hematological abnormalities. There was no transplantation related complications for all the patients. Conclusion UC-MSCT is effective and safe for refractory SLE,but further observation is required to evaluate its long term efficacy.
